
BIO-key Q3 License Fees Up 39%; Net Loss Narrows 8%
BIO-key International announced its third quarter 2026 financial results, reporting a 39% increase in license fee revenue to $1.3M, its third consecutive quarter of double-digit growth. While total revenues slightly decreased to $1.48M from $1.55M year-over-year, the company saw a significant improvement in gross margin to 90% and a narrowed net loss of $(886K). For the first nine months of 2026, revenues grew 14% to $5.5M, and the net loss improved by 42%. The company also highlighted its effective debt-free status after retiring its remaining note and an improved working capital position.
Key Highlights
- Q3'26 license fee revenue rose 39% to $1.3M, marking the third consecutive quarter of double-digit growth.
- Total revenues were $1.48M in Q3'26 vs. $1.55M in Q3'25, with license fee growth offsetting lower hardware and service revenues.
- Q3'26 gross margin improved to 90% from 77% in Q3'25, driven by an increase in high-margin license fees.
- Net loss narrowed 8% to $(886K) in Q3'26 compared to $(965K) in Q3'25.
- 9M'26 revenues grew 14% to $5.5M, with a 42% improvement in net loss to $(1.7M).
- Working capital improved to $3.1M at the close of Q3'26 from $1.4M at year-end 2025.
- BIO-key retired its remaining note in Q3'26, leaving the company effectively debt-free.
Price Impact
More from BKYI
BIO-key International Files S-1 for Resale of 1.24M Shares
BIO-key International Reports Q3 2026 Results: Revenue Down Slightly, Net Loss Improves Year-to-Date
BIO-key International Files S-1 Amendment for Warrant Resale